Video

Data Diversity Initiative: Tackling the Medical Research Data Gap

The data-gap in medical research is well documented, and has serious implications for large sections of the world’s population.

Diseases, treatments and drugs affect people differently according to factors such as race, ethnicity, gender or age, meaning these data gaps in research drastically limit our knowledge to effectively diagnose and treat disease. In the age of digital health, the data-gap can no longer be overlooked if we are to avoid exacerbating existing health inequalities.  

At BenevolentAI, we launched an internal initiative to address this challenge, raise awareness and brainstorm possible solutions to the data diversity problem. We then broadened our scope by engaging with the wider scientific and research community.  

During our inaugural event, we invited a panel of experts to discuss the problem of diversity in medical data, and then invited our audience to participate in an interactive workshop to brainstorm holistic and concrete solutions:  

  • Maria Nelson, Senior Head of Innovation Practice, Digital Catapult  
  • Jackie Hunter, CE Clinical and Strategic Partnerships BenevolentAI  
  • Rob Wilson, Senior Regulatory Consultant, DLRC  
  • Diane Harbison, CEO Decipher Analytics  
  • Dawn Duhaney, Product Manager, Wellcome Trust


More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021